DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 15310.0
(-1.73%)
KRW 15310.0
(-1.73%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 263.36 Billion KRW | 11.0% |
| 2022 | 237.26 Billion KRW | -11.61% |
| 2021 | 268.43 Billion KRW | 12.42% |
| 2020 | 238.77 Billion KRW | 50.21% |
| 2019 | 158.96 Billion KRW | 6.95% |
| 2018 | 148.63 Billion KRW | 46.19% |
| 2017 | 101.67 Billion KRW | 8.95% |
| 2016 | 93.32 Billion KRW | 16.15% |
| 2015 | 80.34 Billion KRW | 18.85% |
| 2014 | 67.6 Billion KRW | 20.68% |
| 2013 | 56.01 Billion KRW | 59.15% |
| 2012 | 35.19 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 263.99 Billion KRW | -5.51% |
| 2024 Q1 | 279.38 Billion KRW | 6.08% |
| 2023 Q3 | 260.01 Billion KRW | 2.89% |
| 2023 Q4 | 263.36 Billion KRW | 1.29% |
| 2023 FY | 263.36 Billion KRW | 11.0% |
| 2023 Q1 | 250.38 Billion KRW | 5.53% |
| 2023 Q2 | 252.7 Billion KRW | 0.92% |
| 2022 Q1 | 258.38 Billion KRW | -3.74% |
| 2022 Q3 | 243.9 Billion KRW | 3.48% |
| 2022 Q2 | 235.7 Billion KRW | -8.78% |
| 2022 FY | 237.26 Billion KRW | -11.61% |
| 2022 Q4 | 237.26 Billion KRW | -2.72% |
| 2021 Q4 | 268.43 Billion KRW | 6.24% |
| 2021 Q1 | 241.73 Billion KRW | 16.54% |
| 2021 FY | 268.43 Billion KRW | 12.42% |
| 2021 Q2 | 262.66 Billion KRW | 8.66% |
| 2021 Q3 | 252.66 Billion KRW | -3.81% |
| 2020 Q4 | 207.43 Billion KRW | -8.33% |
| 2020 Q3 | 226.28 Billion KRW | 5.81% |
| 2020 FY | 238.77 Billion KRW | 50.21% |
| 2020 Q1 | 176.91 Billion KRW | 11.3% |
| 2020 Q2 | 213.86 Billion KRW | 20.88% |
| 2019 Q4 | 158.96 Billion KRW | -6.82% |
| 2019 Q1 | 167.69 Billion KRW | 12.82% |
| 2019 Q2 | 164.43 Billion KRW | -1.94% |
| 2019 Q3 | 170.59 Billion KRW | 3.75% |
| 2019 FY | 158.96 Billion KRW | 6.95% |
| 2018 Q2 | 114.32 Billion KRW | 5.9% |
| 2018 FY | 148.63 Billion KRW | 46.19% |
| 2018 Q4 | 148.63 Billion KRW | 28.89% |
| 2018 Q3 | 115.32 Billion KRW | 0.87% |
| 2018 Q1 | 107.95 Billion KRW | 15.07% |
| 2017 Q4 | 93.81 Billion KRW | -6.86% |
| 2017 FY | 101.67 Billion KRW | 8.95% |
| 2017 Q1 | 84.07 Billion KRW | -3.1% |
| 2017 Q2 | 87.34 Billion KRW | 3.89% |
| 2017 Q3 | 100.72 Billion KRW | 15.32% |
| 2016 Q2 | 81.61 Billion KRW | 3.17% |
| 2016 FY | 93.32 Billion KRW | 16.15% |
| 2016 Q1 | 79.1 Billion KRW | 6.63% |
| 2016 Q3 | 82.22 Billion KRW | 0.74% |
| 2016 Q4 | 86.76 Billion KRW | 5.52% |
| 2015 Q2 | 73.54 Billion KRW | 8.62% |
| 2015 FY | 80.34 Billion KRW | 18.85% |
| 2015 Q3 | 73.39 Billion KRW | -0.21% |
| 2015 Q1 | 67.71 Billion KRW | 0.16% |
| 2015 Q4 | 74.18 Billion KRW | 1.08% |
| 2014 FY | 67.6 Billion KRW | 20.68% |
| 2014 Q1 | 58.79 Billion KRW | 4.95% |
| 2014 Q3 | 66.4 Billion KRW | 9.62% |
| 2014 Q2 | 60.57 Billion KRW | 3.03% |
| 2014 Q4 | 67.6 Billion KRW | 1.81% |
| 2013 Q3 | 55.19 Billion KRW | 8.18% |
| 2013 FY | 56.01 Billion KRW | 59.15% |
| 2013 Q2 | 51.02 Billion KRW | 30.18% |
| 2013 Q4 | 56.01 Billion KRW | 1.49% |
| 2013 Q1 | 39.19 Billion KRW | 11.36% |
| 2012 FY | 35.19 Billion KRW | 0.0% |
| 2012 Q3 | 50.82 Billion KRW | 0.0% |
| 2012 Q4 | 35.19 Billion KRW | -30.74% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 53.19 Billion KRW | -395.057% |
| CMG Pharmaceutical Co., Ltd. | 40.02 Billion KRW | -557.912% |
| Celltrion Pharm, Inc. | 264.97 Billion KRW | 0.61% |
| Huons Global Co., Ltd. | 407.28 Billion KRW | 35.338% |
| Enzychem Lifesciences Corporation | 16.91 Billion KRW | -1456.614% |
| Humedix Co., Ltd. | 21.91 Billion KRW | -1101.76% |
| Boditech Med Inc. | 30.48 Billion KRW | -763.901% |
| EuBiologics Co., Ltd. | 67.82 Billion KRW | -288.3% |
| FutureChem Co.,Ltd | 8.91 Billion KRW | -2852.876% |
| Huons Co., Ltd. | 206.87 Billion KRW | -27.306% |
| BNC Korea Co., Ltd. | 21.94 Billion KRW | -1100.047% |
| AptaBio Therapeutics Inc. | 38.19 Billion KRW | -589.574% |